Kochi M, Fujii M, Takano S, Kato Y, Kawakami T, Kanamori N, Iwai S, Tanaka T
Third Dept. of Surgery, Nihon University School of Medicine.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1535-7.
The pharmacokinetic studies of intraperitoneal cisplatin (CDDP) for gastric cancer were discussed elsewhere, but those studies were investigated in patients with ascites. The purpose of this study is to compare the difference in pharmacokinetics between patients with malignant ascites and those curatively resected without ascites. One hundred mg of CDDP and 300 ml of saline were administered intraperitoneally for 9 curatively resected patients by catheter just after operation, and the same doses of CDDP were administered for 3 advanced or recurrent patients with ascites just after removal of whole fluid. Blood samples were corrected at 6 points after administration. Results were as follows: The 0-t area under the curve (AUC) and the Cmax of both total and free CDDP in the patients without ascites was higher than in the patients with ascites. The 0-infinity AUC and MRT of the ascites patients were higher than in the patients without ascites. These data suggest that intraperitoneal CDDP chemotherapy for gastric cancer as an adjuvant setting is more effective than chemotherapy for advanced malignant ascites patients.
腹腔内顺铂（CDDP）用于胃癌的药代动力学研究在其他地方已有讨论，但这些研究是在有腹水的患者中进行的。本研究的目的是比较恶性腹水患者与无腹水且接受根治性切除患者的药代动力学差异。术后立即通过导管向9例根治性切除患者腹腔内注射100mg CDDP和300ml生理盐水，在抽尽全部腹水后，立即向3例晚期或复发且有腹水的患者腹腔内注射相同剂量的CDDP。给药后在6个时间点采集血样。结果如下：无腹水患者中总CDDP和游离CDDP的0至t曲线下面积（AUC）及Cmax高于有腹水患者。腹水患者的0至无穷大AUC和平均滞留时间（MRT）高于无腹水患者。这些数据表明，作为辅助治疗，腹腔内CDDP化疗用于胃癌比用于晚期恶性腹水患者的化疗更有效。
